Icon Plc (NASDAQ:ICLR) – Equities researchers at William Blair lowered their FY2018 earnings estimates for shares of Icon in a research note issued to investors on Tuesday. William Blair analyst J. Kreger now anticipates that the medical research company will post earnings per share of $5.99 for the year, down from their previous forecast of $6.04. William Blair also issued estimates for Icon’s Q4 2018 earnings at $1.61 EPS, FY2019 earnings at $6.74 EPS and FY2020 earnings at $7.55 EPS.
Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. During the same period in the previous year, the firm posted $1.19 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year.
A number of other research firms also recently issued reports on ICLR. Zacks Investment Research raised shares of Icon from a “hold” rating to a “buy” rating and set a $132.00 price objective for the company in a report on Tuesday. SunTrust Banks reissued a “buy” rating and issued a $138.00 price target on shares of Icon in a research note on Sunday, October 29th. Credit Suisse Group reissued an “outperform” rating and issued a $120.00 price target (up from $105.00) on shares of Icon in a research note on Monday, October 16th. Robert W. Baird reissued a “buy” rating and issued a $123.00 price target on shares of Icon in a research note on Thursday, October 12th. Finally, KeyCorp reissued an “overweight” rating and issued a $125.00 price target (up from $115.00) on shares of Icon in a research note on Monday, November 13th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Icon presently has an average rating of “Buy” and an average target price of $121.82.
Icon (ICLR) traded down $1.44 during midday trading on Thursday, hitting $113.27. 235,981 shares of the stock were exchanged, compared to its average volume of 278,652. Icon has a 52 week low of $76.46 and a 52 week high of $124.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. The company has a market cap of $6,120.00, a P/E ratio of 21.99, a P/E/G ratio of 1.63 and a beta of 0.61.
A number of institutional investors have recently bought and sold shares of ICLR. Koch Industries Inc. lifted its stake in Icon by 17,508.8% in the second quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock worth $659,000 after purchasing an additional 662,357 shares during the last quarter. FMR LLC raised its stake in shares of Icon by 38.4% during the second quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after acquiring an additional 635,950 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Icon by 48.4% during the second quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock valued at $104,488,000 after acquiring an additional 348,292 shares during the last quarter. Mckinley Capital Management LLC Delaware raised its stake in shares of Icon by 2,674.8% during the second quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock valued at $33,104,000 after acquiring an additional 326,320 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Icon by 71.5% during the third quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock valued at $87,513,000 after acquiring an additional 320,356 shares during the last quarter. 89.66% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “FY2018 EPS Estimates for Icon Plc Lowered by William Blair (ICLR)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/13/fy2018-eps-estimates-for-icon-plc-lowered-by-william-blair-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.